文献速递骨质疏松与代谢性骨病

特立帕肽序贯地舒单抗与地舒单抗单药治疗抑制脆性骨折风险的疗效比较

Comparison of the efficacy between sequential therapy with teriparatide and denosumab and denosumab monotherapy in suppressing fragility fracture risk.
PubMed 文献 · Osteoporos Int · 2022-08-04

本回顾性研究分析了2015年8月至2020年10月期间接受地舒单抗治疗超过2年的绝经后女性,比较短期特立帕肽序贯地舒单抗与地舒单抗单药治疗对脆性骨折风险的影响。结果显示,序贯治疗组治疗后骨质疏松性骨折次数少于单药组,且背痛视觉模拟评分改善更明显。

要点

  • 治疗后序贯治疗组骨质疏松性骨折次数少于地舒单抗单药组(0.119±0.348 vs 0.144±0.385,p<0.001)。
  • 治疗前后背痛视觉模拟评分差值在序贯治疗组显著低于单药组(3.246±3.426 vs 1.734±3.049,p<0.001)。
  • 治疗1年和2年后腰椎骨密度增幅序贯治疗组大于单药组(p=0.08,组×时间)。

核心结论

  • 与地舒单抗单药治疗相比,地舒单抗前短期使用特立帕肽在抑制脆性骨折风险方面显示出优异结果。

研究设计与样本

  • 回顾性分析2015年8月至2020年10月期间接受地舒单抗治疗超过2年的绝经后患者数据。
  • 共615例绝经后女性中排除164例(未进行超过2次骨密度检测、失访或接受长期特立帕肽治疗),纳入320例接受地舒单抗单药治疗和131例接受特立帕肽至少3个月后序贯地舒单抗治疗的患者。
  • 采用t检验、卡方检验和线性混合模型分析比较骨质疏松性骨折次数、治疗前后背痛存在情况及治疗期间年度骨密度。

主要发现

  • 治疗前,地舒单抗单药组骨质疏松性骨折次数(均值±标准差:0.459±0.689)少于序贯治疗组(1.037±0.871;p<0.001)。
  • 治疗后,序贯治疗组骨质疏松性骨折次数(0.119±0.348)少于地舒单抗单药组(0.144±0.385;p<0.001)。
  • 治疗1年和2年后,序贯治疗组腰椎骨密度增幅大于地舒单抗单药组(p=0.08,组×时间)。
  • 治疗前后背痛视觉模拟评分差值在序贯治疗组(3.246±3.426)显著低于单药组(1.734±3.049;p<0.001)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: In this retrospective study, the effectiveness of short-term teriparatide with denosumab in reducing fragility fracture risk was determined in comparison with denosumab monotherapy. Administration of sequential teriparatide with denosumab showed excellent outcomes in suppressing the risk for fragility fractures compared with denosumab monotherapy. INTRODUCTION: To determine the effectiveness of short-term teriparatide with denosumab in reducing the risk of fragility fractures in comparison to denosumab monotherapy. METHODS: The data of postmenopausal patients treated with denosumab for > 2 years between August 2015 and October 2020 were retrospectively analyzed. One hundred sixty four postmenopausal women of a total 615 were excluded, since they did not undergo > 2 bone mineral density (BMD) tests, were lost to follow-up, or received long-term teriparatide therapy. Total 320 patients received denosumab monotherapy and 131 patients received teriparatide for ≥ 3 months followed by denosumab. The number of osteoporotic fractures, presence of back pain before and after treatment, and annual BMD during treatment were comparatively assessed using t-test, Chi-square test, and linear mixed model analysis. RESULTS: Before treatment, the denosumab monotherapy group had fewer osteoporotic fractures (mean ± standard deviation; 0.459 ± 0.689) than the sequential therapy group had (1.037 ± 0.871; p < 0.001). After treatment, the sequential therapy group had fewer osteoporotic fractures than the denosumab monotherapy group had (0.119 ± 0.348 versus 0.144 ± 0.385; p < 0.001). At 1 and 2 years after treatment, the increase in lumbar spine BMD was greater in the sequential therapy group than in the denosumab monotherapy group (p = 0.08, group × time). The difference between post and pre-treatment back pain visual analog scale score was significantly lower in the sequential therapy group than in the monotherapy group (3.246 ± 3.426 versus 1.734 ± 3.049; p < 0.001). CONCLUSION: Short-term teriparatide use before denosumab showed excellent outcomes in suppressing the risk of fragility fractures compared with denosumab monotherapy.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Shin JW, He Q, Suk YJ, et al. Comparison of the efficacy between sequential therapy with teriparatide and denosumab and denosumab monotherapy in suppressing fragility fracture risk. Osteoporos Int. 2022. PMID: 35925259. doi:10.1007/s00198-022-06495-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。